Artikel ; Online: Nebulised sargramostim in pulmonary alveolar proteinosis.
British journal of clinical pharmacology
2022 Band 88, Heft 7, Seite(n) 3523–3528
Abstract: Five patients, comprising nine treatment courses of sargramostim use in pulmonary alveolar proteinosis, are described. The prevailing standard of treatment, whole lung lavage (WLL), is highly invasive, resource intensive and carries some procedural risk. ...
| Abstract | Five patients, comprising nine treatment courses of sargramostim use in pulmonary alveolar proteinosis, are described. The prevailing standard of treatment, whole lung lavage (WLL), is highly invasive, resource intensive and carries some procedural risk. Nebulised recombinant human GM-CSF (sargramostim) offers a pharmacological treatment option, allowing patients to be treated at home, possessing potential advantages in patient experience and wider health resourcing. The majority of reported patients described subjective improvement in symptoms along with radiographical improvement, although this did not translate into significant improvement in pulmonary function testing. Drug scarcity and high drug cost remain potential barriers to accessing this treatment, and so careful patient selection and treatment outcome assessment remain as challenging needs. Incorporating the routine assessment of validated patient symptom scores with objective physiological measures will allow prediction of response to treatment and help guide management. This report describes the largest published experience of sargramostim use in Australia. |
|||||
|---|---|---|---|---|---|---|
| Mesh-Begriff(e) | Australia ; Bronchoalveolar Lavage ; Granulocyte-Macrophage Colony-Stimulating Factor/adverse effects ; Humans ; Pulmonary Alveolar Proteinosis/diagnosis ; Pulmonary Alveolar Proteinosis/drug therapy ; Recombinant Proteins | |||||
| Chemische Substanzen | Recombinant Proteins ; sargramostim (5TAA004E22) ; Granulocyte-Macrophage Colony-Stimulating Factor (83869-56-1) | |||||
| Sprache | Englisch | |||||
| Erscheinungsdatum | 2022-02-28 | |||||
| Erscheinungsland | England | |||||
| Dokumenttyp | Journal Article | |||||
| ZDB-ID | 188974-6 | |||||
| ISSN | 1365-2125 ; 0306-5251 ; 0264-3774 | |||||
| ISSN (online) | 1365-2125 | |||||
| ISSN | 0306-5251 ; 0264-3774 | |||||
| DOI | 10.1111/bcp.15266 | |||||
| Signatur |
|
|||||
| Datenquelle | MEDical Literature Analysis and Retrieval System OnLINE |
Volltext online
Zusatzmaterialien
Kategorien
Verfügbar in ZB MED Köln/Königswinter
| Zs.A 1118: Hefte anzeigen | Standort: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG) |
Über subito bestellen
Dieser Service ist kostenpflichtig (siehe Lieferbedingungen von subito). Bestellungen, die einen Artikel nebst Supplementary Material umfassen, werden grundsätzlich wie mehrfache Bestellungen bearbeitet. Gebühren fallen in diesen Fällen für jede einzelne Bestellung an.